Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014

Neuro-Oncology

Volumn 20, Issue , 2018, Pages VII6-VII16

  Gittleman, Haley ^a,b   Boscia, Alexander ^a,b   Ostrom, Quinn T ^a,c   Truitt, Gabrielle ^a,b   Fritz, Yi ^b   Kruchko, Carol ^a   Barnholtz Sloan, Jill S ^a,b  

^a Central Brain Tumor Registry of the United States   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

adults; brain and CNS tumors; incidence; prevalence; survival

Indexed keywords

ADULT; AGE; AGED; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; REGISTER; SEX FACTOR; SURVIVAL RATE; SURVIVORSHIP; TIME FACTOR; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SEX FACTORS; SURVIVAL RATE; SURVIVORSHIP; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 85054505350     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noy090     Document Type: Article

References (22)

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820.
2. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(suppl-5):v1-v88.
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
4. Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585-596.
5. Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867-873.
6. Verhaak RG, Hoadley KA, Purdom E, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
7. Gittleman H, Cote DJ, Ostrom QT, et al. Do race and age vary in nonmalignant central nervous system tumor incidences in the United States? J Neurooncol. 2017;134(2):269-277.
8. Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018;20(4):576-577
9. Ceccarelli M, Barthel FP, Malta TM, et al; TCGA Research Network. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
10. Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al; GliomaScan Consortium. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5): 789-794.
11. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, eds. International Classification of Diseases for Oncology. Third edition. Maryland Heights, MO: Matthews Book Company; 2000.
12. Surveillance Epidemiology and End Results (SEER) Program. SEER Stat software version 8.3.2. 2016; www.seer.cancer.gov/seerstat. Accessed MAY 16,2018).
13. Zhang AS, Ostrom QT, Kruchko C, Rogers L, Peereboom DM, Barnholtz-Sloan JS. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017;19(5):726-735.
14. Surveillance, Epidemiology, and End Results (SEER) Program. www.seer. cancer.gov. SEERStat Database: Populations-Total U.S. (1990-2016), National Cancer Institute, DCCPS, Surveillance Research Program, released November 2017. Accessed May 16, 2018.
15. Michael P. Fay. asht: Applied Statistical Hypothesis Tests. R package version 0.9.3. https://CRAN.R-project.org/package=asht. Accessed May 16, 2018. 2017.
16. R Core Team. R: A Language and Environment for Statistical Computing. Vienne, Austria: R Foundation for Statistical Computing. https://www.Rproject. org/. Accessed May 16, 2018. 2017.
17. Ho VK, Reijneveld JC, Enting RH, et al; Dutch Society for Neuro-Oncology (LWNO). Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50(13):2309-2318.
18. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol. 2017;19(11):1553-1564.
19. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P; EUROCARE-5 Working Group. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2231-2241.
20. Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer. 2003;98(3):603-609.
21. Gabriel A, Batey J, Capogreco J, et al. Adult brain cancer in the U.S. black population: a Surveillance, Epidemiology, and End Results (SEER) analysis of incidence, survival, and trends. Med Sci Monit. 2014;20:1510-1517.
22. Chapter 111: Standards for Tumor Inclusion and Reportability, Table 2. NAACCR Layout Version 18: Comparison of Reportable Cancers: CoC, SEER, NPCR and CCCR. http://datadictionary.naaccr.org/?c=3. Accessed May 16, 2018.